Atara Biotherapeutics, Inc. (ATRA)
6.69
+0.19
(+2.92%)
USD |
NASDAQ |
Nov 18, 16:00
6.69
0.00 (0.00%)
After-Hours: 20:00
Atara Biotherapeutics Enterprise Value : 106.54M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 106.54M |
| November 16, 2026 | 105.52M |
| November 13, 2026 | 118.76M |
| November 12, 2026 | 121.10M |
| November 11, 2026 | 124.16M |
| November 10, 2026 | 122.84M |
| November 09, 2026 | 123.65M |
| November 06, 2026 | 120.49M |
| November 05, 2026 | 121.41M |
| November 04, 2026 | 125.59M |
| November 03, 2026 | 123.86M |
| November 02, 2026 | 126.71M |
| October 30, 2026 | 121.92M |
| October 29, 2026 | 127.22M |
| October 28, 2026 | 128.54M |
| October 27, 2026 | 124.87M |
| October 26, 2026 | 125.38M |
| October 23, 2026 | 127.83M |
| October 22, 2026 | 136.39M |
| October 21, 2026 | 135.57M |
| October 20, 2026 | 133.64M |
| October 19, 2026 | 131.60M |
| October 16, 2026 | 133.84M |
| October 15, 2026 | 138.63M |
| October 14, 2026 | 137.71M |
| Date | Value |
|---|---|
| October 13, 2026 | 135.11M |
| October 12, 2026 | 135.88M |
| October 09, 2026 | 136.90M |
| October 08, 2026 | 134.35M |
| October 07, 2026 | 135.78M |
| October 06, 2026 | 139.65M |
| October 05, 2026 | 136.08M |
| October 02, 2026 | 136.90M |
| October 01, 2026 | 126.50M |
| September 30, 2026 | 126.91M |
| September 29, 2026 | 117.56M |
| September 28, 2026 | 120.58M |
| September 25, 2026 | 124.74M |
| September 24, 2026 | 122.19M |
| September 23, 2026 | 122.38M |
| September 22, 2026 | 125.87M |
| September 21, 2026 | 130.12M |
| September 18, 2026 | 133.05M |
| September 17, 2026 | 133.24M |
| September 16, 2026 | 137.01M |
| September 15, 2026 | 130.69M |
| September 14, 2026 | 128.89M |
| September 11, 2026 | 130.12M |
| September 10, 2026 | 134.94M |
| September 09, 2026 | 135.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
| Savara, Inc. | 821.52M |
| Arrowhead Pharmaceuticals, Inc. | 6.282B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.229M |
| Revenue (Quarterly) | 1.224M |
| Total Expenses (Quarterly) | 3.453M |
| EPS Diluted (Quarterly) | -0.1454 |
| Gross Profit Margin (Quarterly) | 78.35% |
| Profit Margin (Quarterly) | -182.1% |
| Earnings Yield | -18.33% |
| Normalized Earnings Yield | -16.02 |